Company / Current Assets
SAB Biotherapeutics, Inc. Current Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$101.1M
FY2025
5-year range
$23.8M / $101.1M
FY2021-FY2025
Trend
+324.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets changed +325% YoY in FY2025, a notable deviation from the 4-year average annual change of +82%.
Based on SEC 10-K filings.
$101M in FY2025 with a 3-year CAGR of +26.3%.
Improved from $59M to $101M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- +26.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +26.3%, indicating consistent growth.
- In FY2025, current assets increased 324.7% year-over-year.
- Lowest current assets in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $101.1M | +324.7% |
| FY2024 | $23.8M | -59.6% |
| FY2023 | $58.9M | +17.4% |
| FY2022 | $50.2M | +45.7% |
| FY2021 | $34.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026